48 related articles for article (PubMed ID: 19553524)
1. Expression of a modified form of CD4 results in the release of an anti-HIV factor derived from the Env sequence.
Zaldívar I; Muñoz-Fernández MA; Alarcón B; San José E
J Immunol; 2009 Jul; 183(2):1188-96. PubMed ID: 19553524
[TBL] [Abstract][Full Text] [Related]
2. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network.
Zhou P; Goldstein S; Devadas K; Tewari D; Notkins AL
J Immunol; 1998 Feb; 160(3):1489-96. PubMed ID: 9570571
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of HIV-1 gp160-mediated receptor interference: intracellular complex formation.
Martin RA; Nayak DP
Virology; 1996 Jun; 220(2):461-72. PubMed ID: 8661396
[TBL] [Abstract][Full Text] [Related]
4. Retroviral vector-mediated expression in primary human T cells of an endoplasmic reticulum-retained CD4 chimera inhibits human immunodeficiency virus type-1 replication.
San José E; Muñoz-Fernández MA; Alarcón B
Hum Gene Ther; 1998 Jun; 9(9):1345-57. PubMed ID: 9650619
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding.
Li Y; Luo L; Thomas DY; Kang CY
Virology; 2000 Jul; 272(2):417-28. PubMed ID: 10873786
[TBL] [Abstract][Full Text] [Related]
6. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
7. Effects of L- and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication.
Bahbouhi B; Chazal N; Seidah NG; Chiva C; Kogan M; Albericio F; Giralt E; Bahraoui E
Biochem J; 2002 Sep; 366(Pt 3):863-72. PubMed ID: 12071862
[TBL] [Abstract][Full Text] [Related]
8. Replication of primary HIV-1 isolates is inhibited in PM1 cells expressing sCD4-KDEL.
Degar S; Johnson JE; Boritz E; Rose JK
Virology; 1996 Dec; 226(2):424-9. PubMed ID: 8955064
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of HIV-1 replication by backbone cyclic peptides bearing the Rev arginine rich motif.
Chaloin L; Smagulova F; Hariton-Gazal E; Briant L; Loyter A; Devaux C
J Biomed Sci; 2007 Sep; 14(5):565-84. PubMed ID: 17520355
[TBL] [Abstract][Full Text] [Related]
10. An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence.
Barbouche R; Sabatier JM; Fenouillet E
Virology; 1998 Aug; 247(2):137-43. PubMed ID: 9705906
[TBL] [Abstract][Full Text] [Related]
11. Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera.
Ou W; Silver J
Retrovirology; 2005 Aug; 2():51. PubMed ID: 16092970
[TBL] [Abstract][Full Text] [Related]
12. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion.
Ou W; Silver J
Virology; 2006 Jul; 350(2):406-17. PubMed ID: 16507315
[TBL] [Abstract][Full Text] [Related]
13. Generation of H9 T-cells stably expressing a membrane-bound form of the cytoplasmic tail of the Env-glycoprotein: lack of transcomplementation of defective HIV-1 virions encoding C-terminally truncated Env.
Holtkotte D; Pfeiffer T; Bosch V
Retrovirology; 2006 May; 3():27. PubMed ID: 16700925
[TBL] [Abstract][Full Text] [Related]
14. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication.
Auwerx J; Isacsson O; Söderlund J; Balzarini J; Johansson M; Lundberg M
Int J Biochem Cell Biol; 2009 Jun; 41(6):1269-75. PubMed ID: 19038358
[TBL] [Abstract][Full Text] [Related]
15. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
[TBL] [Abstract][Full Text] [Related]
16. Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes.
Beels D; Heyndrickx L; Vereecken K; Vermoesen T; Michiels L; Vanham G; Kestens L
J Virol Methods; 2008 Jan; 147(1):99-107. PubMed ID: 17904649
[TBL] [Abstract][Full Text] [Related]
17. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
[TBL] [Abstract][Full Text] [Related]
18. Intracellular degradation of the HIV-1 envelope glycoprotein. Evidence for, and some characteristics of, an endoplasmic reticulum degradation pathway.
Courageot J; Fenouillet E; Bastiani P; Miquelis R
Eur J Biochem; 1999 Mar; 260(2):482-9. PubMed ID: 10095785
[TBL] [Abstract][Full Text] [Related]
19. Megalomicin inhibits HIV-1 replication and interferes with gp160 processing.
San José E; Muñoz-Fernández MA; Alarcón B
Virology; 1997 Dec; 239(2):303-14. PubMed ID: 9434722
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in the C-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication.
Micoli KJ; Mamaeva O; Piller SC; Barker JL; Pan G; Hunter E; McDonald JM
Virology; 2006 Jan; 344(2):468-79. PubMed ID: 16229872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
